Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23670336 | 1.00 | CYP3A4 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2ABL1 | |
| SCHEMBL19285846 | 1.00 | CYP3A4 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2ABL1 | |
| SCHEMBL24312400 | 0.80 | CYP2D6 (0.38) | CYP3A4HTTSMN1; SMN2SMYD2CYP2D6 | |
| SCHEMBL16225726 | 0.79 | CYP3A4 (0.34) | CYP3A4HTTSMN1; SMN2SMYD2ABL1 | |
| SCHEMBL16225420 | 0.79 | CYP3A4 (0.34) | CYP3A4HTTSMN1; SMN2SMYD2ABL1 | |
| SCHEMBL16225419 | 0.79 | CYP3A4 (0.34) | CYP3A4HTTSMN1; SMN2SMYD2ABL1 | |
| SCHEMBL13739244 | 0.79 | LMNA (0.46) | CYP3A4HTTSMN1; SMN2SMYD2CYP2D6 | |
| SCHEMBL644521 | 0.79 | LMNA (0.46) | CYP3A4HTTSMN1; SMN2SMYD2CYP2D6 | |
| SCHEMBL644520 | 0.79 | LMNA (0.46) | CYP3A4HTTSMN1; SMN2SMYD2CYP2D6 | |
| SCHEMBL7155286 | 0.79 | CYP2D6 (0.37) | CYP3A4HTTSMN1; SMN2SMYD2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210230189-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2021-07-29 | — | — | US | disclosed |
| WO-2017147410-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2017-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230189-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | CYP3A4 4326/4885HTT 1584/4885SMN1; SMN2 1807/4885 |
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | CYP3A4 4326/4885HTT 1584/4885SMN1; SMN2 1807/4885 |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | CYP3A4 4326/4885HTT 1584/4885SMN1; SMN2 1807/4885 |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | CYP3A4 4326/4885HTT 1584/4885SMN1; SMN2 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.